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Abstract: Serine Protease Autotransporters of Enterobacteriaceae (SPATEs) constitute a 
large family of proteases secreted by Escherichia coli and Shigella. SPATEs exhibit two 
distinct proteolytic activities. First, a C-terminal catalytic site triggers an intra-molecular 
cleavage that releases the N-terminal portion of these proteins in the extracellular medium. 
Second,  the  secreted  N-terminal  domains  of  SPATEs  are  themselves  proteases;  each 
contains a canonical serine-protease catalytic site. Some of these secreted proteases are 
toxins, eliciting various effects on mammalian cells. Here, we discuss the biogenesis of 
SPATEs and their function as toxins. 
Keywords: SPATE; autotransporters; pathogenic E. coli; Shigella; EspP; Pet; EspC; Sat; 
Vat; Hbp; EpeA; Pic; SepA; SigA; Tsh 
 
1. Introduction 
1.1. The Autotransporter Pathway 
SPATE  (Serine  Protease  Autotransporters  of  Enterobactericeae)  is  a  family  of  extracellular 
proteases produced by the Enterobacteriaceae. As their name indicates, they are “autotransporters” 
(ATs), meaning they are secreted by the Type Va secretion system from gram-negative bacteria. ATs 
are very diverse in their function (adhesin, protease, esterase, lipase, etc.) [1], but it is assumed that 
they share the same export mechanism. They are recognized based on their common organization: they 
are comprised of an N-terminal, sec-dependent, signal-peptide required for targeting to- and export 
through the inner membrane, followed by a “passenger domain” (which is the functional, secreted part of 
the protein), and a C-terminal -domain (or „translocator” domain), which folds as a -barrel in the 
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outer  membrane  (OM).  The  C-terminal  -domain  is  necessary  for  translocation  of  the  passenger 
domain through the OM [2,3]. The region linking the passenger domain and the -barrel is referred to 
as the “linker domain” (Figure 1) [2,3]. 
Despite their diversity in function, most autotransporter passenger domains fold or are predicted to 
fold as -helices [4–8]. Usually, the -helix forms a “spine” to which additional, functional domains 
are attached. However, exceptions exist: the recently crystallized EstA autotransporter from Pseudomonas 
aeruginosa harbors a globular, -helical passenger domain, with no -helix domain (Figure 1) [9].  
Autotransporter beta-domains are structurally very conserved. The three AT -domains crystallized 
to date form 12-stranded -barrels that are almost perfectly superimposable [9–11]. Approximately 30 
amino acid residues, located upstream from the -barrel-forming region in the primary sequence, form 
an -helix in the pore of the -barrels and connect the N-terminus of the -barrel with the extracellular 
passenger domain (Figure 1). This region, also called the “linker domain” is necessary for the folding 
and stability of the -barrel [10,12,13].  
Although  the  domain  organization  and,  to  a  certain  degree,  the  three-dimensional  structure  of 
autotransporters is conserved, their sequences show only weak homology. However, AT subfamilies 
can be identified based upon increased amino-acid sequence identity. One of them is the SPATE 
subfamily, initially identified by Henderson et al. [2]. 
1.2. The SPATE Subfamily of Autotransporters 
The SPATE subfamily of autotransporters is currently -composed of: EspP (extracellular serine 
protease plasmid (pO157)-encoded), initially designated PssA (protease secreted by STEC), and EpeA  
(EHEC  plasmid-encoded  autotransporter)  from  enterohaemorrhagic  E.  coli  (EHEC)  [14–16],  Pet 
(plasmid-encoded  toxin)  from  enteroaggregative  E.  coli  (EAEC)  [17],  Pic  (protease  involved  in 
intestinal colonization) from EAEC, uropathogenic E. coli (UPEC) and Shigella [18,19], EspC (EPEC 
secreted  protein  C)  and  Hbp  (hemoglobin  protease  or  hemoglobin  binding  protein)  from 
enteropathogenic E. coli (EPEC) [20,21], Sat (secreted autotransporter toxin) from UPEC [22], Tsh 
(temperature-sensitive  hemagglutinin)  and  Vat  (vacuolating  autotransporter  toxin)  from  avian 
pathogenic E. coli (APEC) [23,24], EatA (ETEC autotransporter A) from enterotoxinogenic E. coli 
(ETEC)  [25],  EspI  (E.coli  secreted  protease,  island-encoded)  from  Shiga  toxin  producing  E.  coli 
(STEC) [26], EaaA and EaaC from the non-pathogenic ECOR-9 E. coli strain [27]; as well as ATs 
from Shigella flexneri: SepA (Shigella extracellular protein A) [28], SigA [29], and one protein from 
Salmonella bongori: Boa (bongori autotransporter) [30]. Yen et al. also reported the identification of 
additional SPATEs in Citrobacter and E. coli strains E22, B7A, and F11 [31]. 
Proteins belonging to the SPATE family display the typical characteristics of autotransporters: they 
are composed of a signal sequence, a passenger domain secreted in the extracellular medium, and a  
C-terminal -domain necessary for translocation of the passenger domain through the outer membrane. 
The crystal structure of one SPATE passenger domain has been solved (Hbp), as well as that of one 
SPATE  -domain  (EspP)  [5,11].  Like  for  other  ATs,  the  EspP  -domain  folds  as  a  12-stranded  
-barrel, whereas the Hbp passenger domain forms a helix to which a protease domain is attached 
(Figure 1). Toxins 2010, 2                         
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Figure  1.  Autotransporter  Proteins:  Common  organization  and  structure  (A).  Domain 
organization of AT proteins. (B). Crystallographic structure of representative AT domains. 
Passenger domains are shown in red. Hbp: Hemoglobin protease from E. coli (PDB entry 
1WXR)  [5],  Prn:  Bordetella  pertussis  Pertactin  (PDB  entry  1DAB)  [4],  VacA: 
Helicobacter pylori vacuolating toxin fragment p55 (PDB entry 2QV3) [7], and IgAP: 
Haemophilus influenzae immunoglobulin A1 protease (PDB entry 3H09) [8]. -domains 
are shown in green: EspP from E. coli O157:H7 (PDB entry 2QOM) [11], NalP from 
Neisseria  meningitidis  (PDB  entry  1UYN)  [10],  EstA  from  Pseudomonas  aeruginosa 
(PDB entry 3KVN) [9]. Linker domains are shown in magenta. 
 
 
SPATEs have been grouped in a family based on several criteria: 
(1) They display a very conserved -domain. In pair-wise comparison, sequence identity among 
SPATE proteins ranges from 25 to 55%. However, the conserved residues are not equally spread over 
the length of the proteins. The passenger domains are variable in length (between 954 and 1050 residues) 
and show between 23 and 50% amino-acid identity. In contrast, the -domains are all exactly 277-residues 
long and 60 to 99% identical. A few SPATEs are more conserved: EaaA and EaaC, as well as Tsh and 
Hbp are almost identical (EaaA and EaaC differ by eight residues, Tsh and Hbp differ by only two). In 
addition, Vat and Tsh/Hbp are 77.5% identical and SepA and EatA are 72.8% identical. In these pairs, Toxins 2010, 2                         
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both the -domains and the passenger domains are conserved, with most of the divergence occurring at 
the N-terminus of the protein.  
(2) As their name specifies, SPATEs are proteases. They all ccontain a conserved serine-protease 
motif (GDSGS where S is the catalytic serine) at the N-terminus of their passenger domain (between 
residues 250–270).  
(3) Whereas some autotransporters remain intact in the outer membrane after secretion, others are 
cleaved between the passenger domain and the -domain, thus releasing the passenger domain into the 
extracellular milieu. All SPATEs are cleaved between the passenger domain and the -domain after 
translocation  of  their  passenger  domain  through  the  outer  membrane.  The  cleavage  occurs  at  a 
conserved FxxEVNNLNK site located in the linker domain, with the processing always occurring 
between the two asparagines. Various mechanisms have been involved in autotransporter cleavage [3]. 
In the case of SPATE proteins, the processing is thought to be autoproteolytic, intra-molecular, and 
catalyzed by the -domain (see below). 
(4) All SPATE proteins have unusually long (>49 amino-acids) signal sequences. This type of 
signal  sequence  is  found  in  ~10%  of  autotransporters,  as  well  as  in  proteins  secreted  by  the  
“two-partner secretion system” (or type Vb secretion system).  
(5) SPATEs are usually among the most abundant proteins secreted by the parental strain, at least in 
laboratory conditions. 
2. SPATEs Genes: Location and Evolution 
SPATE-encoding genes are located on mobile genetic elements, such as plasmids (EspP [14–16], 
Pet [17], EatA [25], EpeA [16], Hbp [5], SepA [28], Tsh [32]); prophages (EaaA and EaaC [27]), or 
chromosomal pathogenicity islands (Sat [22], EspI [26], SigA [29], EspC [33], Pic [19,34], Vat [35]). 
Most of these genes are flanked by IS-like elements and have GC% significantly different from the 
genome of their producing strain [2,15,17,21,22,32,33,35]. Altogether, this suggests that SPATE genes 
have been acquired by horizontal gene transfers. Horizontal gene transfers have been reported for  
non-SPATE autotransporter genes [36], and have been proposed in the case of the SPATE Boa, which 
is only detected in a single species of Salmonella [31]. In addition, a SPATE gene (eaaC) located on a 
prophage, could be experimentally transferred between two E. coli strains by transduction [27]. Still, 
the phylogenic clustering of AT proteins also suggests that if horizontal transfer events occurred, they 
were rare and limited to phylogenetically related species. Yen et al. proposed that most ATs instead 
evolved  through  speciation  and  duplication  events  rather  than  horizontal  gene  transfer  [37].  The 
presence of the two identical genes eaaA and eaaC in the ECOR-9 strain of E. coli indeed suggests 
that duplication of SPATE genes occurred [27]. 
In addition, the high conservation of the -domain sequence compared with the passenger domain 
sequence,  suggests  that  ATs  might  have  arisen  from  the  fusion  between  a  common,  generic 
translocator domain and various functionally divergent passenger domains [38]. This hypothesis is 
supported in the SPATE family where the -domains are much more conserved than the passenger 
domains. Several members actually share almost identical -domains but divergent passenger domains 
(for example, EspI, EspP, and EpeA -domains are >95% identical, whereas their passenger domains 
are less than 35% identical; Pet and EaaA/EaaC -domains are >90% identical whereas their passenger Toxins 2010, 2                         
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domains are <25% identical). After fusion to the translocator domain, the passenger domains might 
also have evolved independently even further, through point mutations and recombination events. For 
example, the gene encoding EspP displays a genetic heterogeneity that led to the identification of four 
different alleles [39]. This heterogeneity is due to point mutations, as well as recombination events. In 
particular, two of these alleles acquired a DNA fragment from espI, another SPATE-encoding gene 
[39],  which  indicates  that  recombination  between  SPATE  genes  occurred.  These  events  have  a 
reasonable chance of taking place; some strains possess several SPATE genes (for example the E. coli 
O113:H21 strain EH41 possess epeA and espP on a plasmid and espI on the chromosome [16], and 
UPEC CFT073 encodes Sat, Pic and Vat [19]).  Recombination events between SPATE passenger 
domains are also suggested by phylogenetic studies [31,40]. Ultimately, this complex evolution would 
have led to the extreme functional diversity observed within autotransporters in general, but also in the 
more closely related SPATEs.  
3. Regulation of Expression 
The exact mechanism by which SPATE expression is regulated has not been studied in much detail. 
Their expression seems to be regulated by environmental stimuli (temperature, oxygen availability, 
pH) as well as by quorum sensing. In contrast with Pet, for which expression does not seem to be 
affected by temperature [17], SigA, Pic, EpeA, EspP, EspC, Tsh, and SepA are all thermoregulated, 
showing  maximal  expression  at  37  ° C  compared  with  lower  (20–30  ° C)  or  higher  (40–42  ° C) 
temperatures  [14,16,18,23,28,29,35,41,42].  Such  thermoregulation  is  often  observed  for  virulence 
factors that need only to be expressed in the host in the context of infection but that are not necessary 
for the bacterium to survive in the environment. The expression of several SPATEs in the context of 
infection  has  actually  been  confirmed  by the detection  of anti-SPATE antibodies in the  serum of 
infected patients [14,15,17,43–45]. Immune response to SPATEs was also observed in animal models 
of  infection  for  Sat  and  SepA  [22,28].  The  mechanism  or  pathways  involved  in  SPATE 
thermoregulation are unknown. Expression of some SPATEs is also pH-dependent, with optimum 
expression at alkaline pH (pH 7.0–9.0 for EspP [14], pH 8.0 for EpeA [16], pH 9.0 for Pic [18]). Hbp 
production was enhanced under anaerobic conditions [5], whereas osmolarity had no effect on Pic or 
Tsh expression [18,42]. Interestingly, EspC expression, in addition to being regulated by temperature, 
is also dependent upon the medium composition: the protein is expressed in tissue culture medium 
such as MEM medium, but not in LB or M9 medium. Additionally, EspC expression increases upon 
contact with host cells [20,41]. espC transcription is also regulated by quorum sensing, through the 
Per/Ler regulatory pathway in EPEC. Although Ler is also present in EHEC, it does not influence 
EspP expression [46].  
4. Biogenesis 
Autotransporters, including SPATE proteins, are transported through the inner membrane via the 
Sec-translocon.  Once  in  the  periplasm,  the  C-terminal  domain  folds  as  a  -barrel  in  the  outer 
membrane, forming a pore. The passenger domain is then translocated through the outer membrane, 
cleaved from the -barrel and released in the extracellular medium, where it will fulfill its function, 
usually related to the virulence of the producing strain.  Toxins 2010, 2                         
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4.1. Export through the Inner Membrane 
After synthesis, SPATE proteins are targeted to the Sec-translocon which catalyses their transport 
through  the  inner-membrane.  To  be  targeted  to  the  Sec-translocon,  presecretory  proteins  need  to 
harbor a N-terminal, cleavable, “signal sequence”. These sequences are usually ~20–30 residues long, 
highly  variable  in  sequence  and  organized  in  three  domains:  a  N-terminal,  relatively  basic  
“N-domain”, a “H-domain” rich in hydrophobic residues, and a “C-domain” where the cleavage by 
signal peptidase occurs. In the case of SPATE proteins, the signal sequence is at least 49 residues long 
and is comprised of a ~25 residues N-terminal conserved extension and a C-terminal non-conserved 
region,  which  resembles  a  conventional  signal  peptide  (Table  1).  The  origin  of  the  N-terminal 
extension is unknown, it is found in ~10% of all autotransporters, but in 100% of SPATEs [3]. It is 
highly conserved, with an amino-acid sequence identity ranging between 37.5% and 96% in the SPATE 
family.  An  increase  in  identity  in  the  N-terminal  extension  does  not  correlate  with  an  increase  in  
-domain  or  passenger  domain  amino-acid  identity,  suggesting  that  this  extension  was  acquired 
independently from either of these domains. 
Table 1. Sequence comparison of SPATEs signal sequences. Residues strictly conserved 
are highlighted in red, residues most frequently found at each position are highlighted in 
blue  and  conservative  mutations  are  highlighted  in  grey.  The  cleavage  site  for  signal 
peptidase is indicated by the symbol <>. 
  N-terminal extension  N-Domain  H-domain  C-domain 
Boa  MNKIYALKYSVRQGALVPVSELAT  HVKKSSRTGLIKK  IIPSLLINTILLGYSVS  SLA
57<>SVV 
EaaA  MNRIYSLRMNDRKE-LVAVAETAG  GRKKSSG  IPGAGMLSRLLLASG  AVA
48<>GVL 
EaaC  MNRIYSLRMNDRKE-LVAVAETAG  GRKKSSG  IPGAGMLSRLLLASG  AVA
48<>GVL 
EatA  MNKVFSLKYSFLAKGFIAVSELAR  RVSVKGKLK  SASSIIISPITIAIVSYAPP  SLA
56<>ATV 
EpeA  MNKIYSLKYSSLTGGLIAVSELSK   KVKGKTGRK  LMTASVALSVSLSALP  VEA
52<>STV 
EspC  MNKIYALKYCHATGGLIAVSELAS   RVMKKAAR  GSLLALFNLSLYGAFLSA  SQA
53<>AQL 
EspI  MNKIYALKYSSLTGGLIAVSELSK  KVTGKTGRR  LMTVSLVLSVTLSALP  GKA
52<>STV 
EspP  MNKIYSLKYSHITGGLIAVSELSG  RVSSRATGKKKHKR  ILALCFLGLLQSSY  SFA
55<>SQM 
Hbp  MNRIYSLRYSAVARGFIAVSEFAR  KCVHKSVRR  LCFPVLLLIPVLFSAG  SLA
52<>GTV 
Pet  MNKIYSIKYSAATGGLIAVSELAK  KVICKTNRK  ISAALLSLAVISYTNI  IYA
52<>ANM 
Pic  MNKVYSLKYCPVTGGLIAVSELAR  RVIKKTCRRLT  HILLAGIPAICLCYSQI  SQA
55<>GIV 
Sat  MNKIYSLKYSAATGGLIAVSELAK  RVSGKTNRK  LVATMLSLAVAGT  VNA
49<>ANI 
SepA  MNKIYYLKYCHITKSLIAVSELAR   RVTCKSHRRLSRR  VILTSVAALSLSSAWP  ALS
56<>ATV 
SigA  MNKIYSLKYSHITGGLVAVSELTR  KVSVGTSRKK  VILGIILSSIYGSYGET  AFA
54<>AML 
Tsh  MNRIYSLRYSAVARGFIAVSEFAR  KCVHKSVRR  LCFPVLLLIPVLFSAG  SLA
52<>GTV 
Vat  MNKIYALKYCYITTTVKVVSELAR  RVCKGSTRRGKR  LSVLTSLALSALLPTV  AGA
55<>STV 
The  C-terminal  “classical”  signal  peptide  is  necessary  and  sufficient  for  inner  membrane 
translocation.  In  contrast,  the  N-terminal  extension  is  not  a  targeting  signal  by  itself,  and  is  not 
necessary for secretion through the inner membrane [47–50]. However, this sequence influences the 
targeting pathway to the inner membrane. Secreted proteins can be targeted to the Sec-translocon 
either via the SRP (signal recognition particle) pathway, or through a SecB-dependent pathway. The 
SRP  ribonucleoprotein  complex  promotes  cotranslational  targeting  of  protein  by  interacting  with Toxins 2010, 2                         
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highly hydrophobic signal sequences when they emerge from the ribosome. In the SecB-dependent 
pathway, presecretory proteins are targeted to the inner membrane post-translationally by a mechanism 
that  requires  the  SecB  chaperone  to  keep  the  protein  in  a  secretion-competent  state  within  the 
cytoplasm.  Both  EspP  and  Pet  are  secreted  post-translationally,  in  a  SecB-dependent  manner. 
However, the deletion of the N-terminal extension increases the Pet rate of inner membrane secretion 
and reroutes EspP to the SRP pathway [48,49]. This suggests that the N-terminal extension may either 
bind to an unknown cytoplasmic factor that delays inner membrane translocation, or prevents SRP 
from binding to the C-terminal region of the signal peptide [48,49]. In contrast to EspP and Pet, Hbp is 
targeted to the inner membrane cotranslationally, in a SRP-dependent fashion [50,51]. The difference 
in  targeting  observed  between  these  SPATE  proteins  might  be  explained  by  the  increased 
hydrophobicity of the Hbp H-domain compared with EspP and Pet [50]. Since SRP has higher affinity 
for hydrophobic signal sequences, it is possible that the higher hydrophobicity of this particular signal 
peptide  overcomes  the  inhibitory  effect  of  the  N-terminal  extension.  However,  increasing  the 
hydrophobicity  of  EspP  H-domain  by  site-directed  mutagenesis  did  not  influence  the  targeting 
pathway of this SPATE [48]. Another possibility might be that small amino-acid variations, in the  
N-terminal extension itself, affect the ability of this sequence to inhibit SRP binding. It is already 
known  that  mutation  of  the  conserved  Asn  in  position  2  of  the  extension  is  sufficient  to  abolish  
SRP-binding inhibition and reroute EspP to the SRP pathway [48]. However, other positions might 
also be important in inhibiting SRP binding. In this regard, it is interesting to note that EspP and Pet 
extensions have higher identity to each other than to the Hbp extension (Table 1). Thus, it might be 
interesting to test whether exchanging Hbp and EspP/Pet N-terminal extensions affect SRP binding or 
the targeting pathway of these proteins to the inner membrane, or both. 
4.2. Transport through the Periplasm 
In  addition  to  a  role  in  protein  targeting,  it  was  also  proposed  that  the  conserved  N-terminal 
extension could affect later steps in biogenesis. Indeed, despite the fact that the signal sequence is 
cleaved  when  the  protein  crosses  the  inner  membrane,  Szabadi  et  al.  showed  that  deleting  the  
N-terminal extension severely impairs EspP transport through the outer membrane [47]. To explain 
this observation, they proposed a model in which the N-terminal extension delays EspP release in the 
periplasm  via  a  prolonged  interaction  with  the  Sec-translocon.  This  delay  would  in  turn  prevent 
misfolding of the protein in the periplasm, and allow proper transport through the outer membrane. In 
contrast  however,  deletion  of  the  N-terminal  extension  did  not  affect  Hbp  outer  membrane 
translocation, since the protein was released normally in the extracellular medium [50]. Whether the 
disparity in results obtained between EspP and Hbp are due to variations in experimental conditions or 
intrinsic differences between Hbp and EspP (such as folding rate of the passenger domain or ability of 
the extension to tether the proteins to the Sec-translocon) is currently unknown. In any case, if this 
extension  is  indeed  important  for  autotransporter  biogenesis,  one  might  ask  why  only  ~10%  of 
autotransporters harbor this sequence. It is possible that some autotransporters (especially SPATEs), 
are  particularly  prone  to  aggregation  in  the  periplasm  and  thus  need  this  sequence  for  secretion 
through the envelope to occur. ATs lacking this sequence might be less prone to aggregation or have 
evolved other mechanisms to prevent misfolding in the periplasm. Such mechanisms could involve a Toxins 2010, 2                         
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reduced folding rate or interaction with specific periplasmic chaperones. The passenger domain of 
pertactin, a non-SPATE AT that does not possess a N-terminal extension, indeed folds very slowly in 
vitro, without forming aggregates [52]. However, this does not appear to be specific to AT missing the 
N-terminal extension, since the folding of the SPATE Pet was not significantly different from Pertactin 
in vitro [53]. In vitro folding is nevertheless very different from in vivo events, where secreted proteins 
might encounter chaperones in the periplasm. Indeed, two SPATE “stalled” mutants have recently 
been used to identify potential partners of SPATE proteins during secretion. Using this strategy, Hbp 
was  found  to  interact  with  the  periplasmic  chaperone  SurA,  whereas  EspP  passenger  domain  
cross-linked  with  both  SurA  and  Skp  [54,55].  Although  direct  interactions  between  the  
wild-type  SPATEs  and  the  respective  chaperones  were  not  observed  in  these  studies,  wild-type 
denatured EspP was shown to interact with SurA, Skp, and DegP in surface plasmon resonance and 
two-hybrid assays [56]. In addition, experiments with E. coli mutant strains further suggest that these 
periplasmic chaperones are important for SPATE secretion. Indeed, EspP secretion was reduced in 
surA,  skp,  or  degP  mutants  of  E.  coli,  and  Hbp  secretion  was  affected  in  a  surA  strain  [54,56]. 
Interestingly, surA deletion had a much more pronounced effect on Hbp biogenesis than with EspP. In 
a  surA  strain,  EspP  is  translocated  through  the  OM  and  cleaved,  but  the  level  of  cleaved  EspP 
passenger domain found in the extracellular medium was slightly reduced compared with the level 
found in a wild-type E. coli strain [56]. Hbp, in contrast, is unprocessed in a surA E. coli strain [54]. 
Hbp secretion through the outer membrane is not affected by the absence of the N-terminal extension, 
which suggests (according to the model proposed by Szabadi et al.) that Hbp extension does not tether 
the protein to the inner membrane like it apparently does for EspP. In the absence of such tethering, 
Hbp might be more dependent on chaperone like SurA to avoid misfolding in the periplasm, which 
would explain the more pronounced effect of surA mutation on Hbp biogenesis compared with that of 
EspP. Thus, SPATEs apparently need to be kept in a secretion-competent conformation in order to be 
secreted properly through the outer membrane. This is apparently possible either through a prolonged 
interaction  with  the  Sec-translocon  or  via  interaction  with  periplasmic  chaperones,  or  both.  The 
question of what exactly is a “secretion-competent” state for autotransporters is still a matter of debate 
(see below). 
4.3. Transport through the Outer Membrane 
Once in the periplasm, the autotransporter  domain is inserted into the outer membrane (OM), 
where it forms a -barrel. The passenger domain is then transported to the extracellular medium. 
Deletion of an AT  domain abolishes the translocation of the passenger domain through the OM; this 
domain  is  thus  essential  to  the  translocation.  However,  its  exact  role  is  still  unknown.  Because  
β-barrels  can  form  pores  in  the  OM,  it  was  initially  proposed  that  AT  passenger  domains  are 
translocated  through  the  OM  via  the  pore  formed  by  their  associated  -barrel  (hence  the  name 
“autotransporters”) [57]. Accordingly, the crystallographic structures of the 3 AT domains solved to 
date (Figure 1) showed that the C-terminus of the passenger domain resides in the center of the pore 
formed by the  domain [9–11]. These crystallographic structures also showed that the pores of these 
barrels are too narrow (~10 Å) to translocate folded passenger domains [9–11]. This is inconsistent 
with numerous studies reporting the translocation, by ATs, of folded passenger domains through the Toxins 2010, 2                         
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OM. As a consequence, the idea of ATs mediating their own transport through the OM has been 
challenged.  Today,  three  models  have  been  proposed  to  explain  translocation  of  AT  passenger 
domains through the OM [3,58]. 
(1) In the “hairpin” model, the passenger domain is transported through the pore of the -barrel, 
with the C-terminus of the passenger first. This model implies that the passenger is unfolded when it 
crosses the OM. 
(2) A study with IgA protease, an AT from Neisseria, showed that this particular AT is able to form 
multimers in the OM, which led to a second model in which the passenger domain translocation would 
occur through a central channel formed by the walls of 6 or more -barrels [59]. Because the pore 
formed by these oligomers would be wider than the pore formed by an individual AT -barrel, it 
would be able to translocate folded domains across the OM.  
(3) Finally, a third model proposes that AT are inserted in the OM via the general OM-protein 
assembly  machinery  Omp85/YaeT  [10,58,61],  and  that  the  passenger  domain  translocation  is 
concomitant to the insertion of the AT in the OM.  
SPATEs -domains for which information on oligomerization states is available (EspP and Tsh) 
were  found  to  be  monomeric  [11,61,62].  These  studies  suggest  that  the  translocation  of  SPATE 
passenger domains through the OM does not occur via an oligomeric pore formed by their  domains. 
In addition, folding of a heterologous passenger domain (cholera toxin B) in the periplasm does not 
prevent its translocation across the OM by the EspP -domain. This argues against the hairpin model 
[62]. In contrast, Jong et al. found that although the Hbp passenger domain folds to a certain extend in 
the periplasm, tightly folded domains attached to this passenger can block translocation [63]. Finally, 
recent studies found that EspP and Hbp both interact with Omp85/YaeT during secretion, and that 
depletion  of  Omp85  strongly  affects  the  secretion  of  Hbp  through  the  bacterial  envelop  [54–56]. 
Altogether, these results suggest that SPATEs transport their passenger domain through the OM via a 
mechanism  depending  on  both  their  own  -domains  and  Omp85.  The  precise  mechanism  of  this 
translocation however, is still unknown. 
4.4. Cleavage 
Whereas some autotransporters remain intact in the outer membrane after secretion (e.g., EstA, 
Figure 1), others are cleaved between the passenger domain and the -domain, thus releasing the 
passenger domain in the extracellular milieu. Cleavage of the passenger domain from the -domain 
can occur by various mechanisms. Certain ATs are cleaved autoproteolytically, with a protease domain 
located in the passenger domain being necessary for processing. One AT (IcsA from Shigella flexneri), 
is cleaved by an outer membrane protease homologous to OmpT (IcsP), and some autotransporters are 
cleaved  by  other  ATs  (for  example,  NalP  cleaves  IgA-P)  [3].  All  SPATEs  are  cleaved,  after 
translocation of their passenger domain through the outer membrane, between the passenger domain 
and  the  -domain.  The  cleavage  occurs  at  a  conserved  FxxEVNNLNK  site  located  in  the  linker 
domain, with the processing always occurring between the 2 asparagines [17,18,42]. Very early on, it 
was shown that the conserved serine protease site located in the first third of the passenger domain was 
not involved in the processing of the passenger domain from the -domain [14,20,25,26,28,42,47]. In 
addition, expression of SPATEs in strains deleted of outer membrane or periplasmic proteases such as Toxins 2010, 2                         
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OmpT, OmpP, or DegP, did not affect cleavage either [14,17,28,42]. Recently, we found that the 
conserved cleavage site (EVNNLN) is actually located in the pore of EspP -barrel after translocation, 
suggesting  that  it  might  not  be  accessible  to  any  periplasmic  or  outer  membrane  proteases.  As  a 
consequence, we tested the hypothesis that the SPATE -barrel could be itself the protease responsible 
for cleavage. Indeed, we found that purified EspP was still processed in vitro and that mutations in 
EspP -barrel abolish cleavage. Specifically, we identified two positions that are crucial for cleavage: 
Asp1120, which is located in the -domain and is facing the pore of the barrel, and Asn1023, which is 
the  residue  just  upstream  from  the  cleavage  site  [64].  The  implication  of  one  aspartate  and  one 
asparagine in an autoproteolytic reaction, with the Asn at the P1 residue of the cleavage site, was 
highly reminiscent of the autoproteolytic reaction proposed for the capsid protein of Nodavirus [65]. 
As a consequence, we proposed that EspP is cleaved by a similar autoproteolytic mechanism, with the 
cyclization of the Asn located at position P1 of the cleavage site being catalyzed by the Asp in position 
1120 of the -barrel (Figure 2) [64].  
Figure  2.  Proposed  mechanism  of  SPATEs  autoproteolytic  processing.  (A).  EspP  was 
proposed to be cleaved by an autoproteolytic mechanism taking place in the pore of the 
autotransporter -barrel. (B). After translocation of the passenger domain across the OM, 
Asn1023 is positioned close to Asp1120. As a consequence of hydrogen bonding between 
the  two  side  chains,  Asn1023  amide  group  performs  a  nucleophilic  attack  on  the  
Asn1023–Asn1024  peptide  bond.  This  reaction  results  in  Asn1023  cyclization  and  the 
production of a succinimide intermediate at the C-terminus of the passenger domain, which 
will be ultimately hydrolyzed into a mixture of asparagine and iso-asparagine [64,65]. 
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In such a mechanism, the cyclization of the catalytic Asn results in the formation of a succinimide 
intermediate, which is then hydrolyzed into either asparagine or iso-asparagine [65]. Accordingly, 
,analysis of the secreted EspP passenger domain by mass spectrometry showed that the passenger 
domain is secreted in two forms: one being 18 Da smaller than the theoretical mass of the domain and 
probably corresponds to the succinimide intermediate, and one form corresponding to the passenger 
domain with either an asparagine or iso-asparagine at the C-terminus [64]. We also found a mixture of 
Asn  and  Iso-Asn  at  the  C-terminus  of  the  secreted  EspP  passenger  domain  [64].  Although  outer 
membrane proteases are well documented (referred to as “omptins”), this is the first example of an OM 
protease that possesses a catalytic site inside the pore of the barrel. Omptins‟ catalytic residues, in 
contrast, are located in the extracellular loops of the protein. The SPATE intra-barrel cleavage was 
further confirmed by the resolution of EspP -barrel structure (post-cleavage), which clearly shows a 
fragment going half-way through the pore of the barrel, instead of an -helix reaching the extracellular 
side of the membrane, which is seen in ATs for which cleavage takes place in the extracellular medium 
(Figure 1) [11].  
The residues important for cleavage are conserved in all SPATEs, suggesting that all members of 
this  family  are  processed  by  the  same  autoproteolytic  mechanism.  Although  this  has  not  been 
confirmed,  Kostakioti  et  al.,  found  that,  like  in  EspP,  mutation  of  the  Asn  at  position  P1  of  the 
cleavage  site  abolishes  cleavage  in  Tsh  [67].  In  addition,  several  mutations  located  in  the  linker 
domain also affect cleavage in both EspP and Tsh [64,66]. However, some of these mutations also 
affect passenger domain translocation in Tsh, whereas they did not in EspP [64,66]. Interestingly, we also 
found  that  this  mechanism  is  conserved  in  certain  non-SPATE  autotransporters,  such  as  the 
autotransporters BrkA and Pertactin from Bordetella pertussis [64]. The cleavage of SPATEs is very 
fast, with most of the protein being cleaved in only few minutes [47]. The passenger domain is also 
quickly released into the medium, but some cleaved passenger domain also remains associated with 
cells for an undetermined time [47]. Considering the variety of cleavage mechanisms found among 
ATs, why SPATEs have evolved an intra-barrel mechanism is puzzling, especially considering the fact 
that they possess a proteolytic activity in their passenger domain that they could potentially use to 
separate  the  passenger  from  the  -domain,  in  a  mechanism  similar  to  IgAP.  This  mechanism  is 
probably not just a consequence of the fusion of the generic -barrel, since it is also found in some 
Bordetella ATs, which have very low homology with SPATE -domains. In theory, intramolecular 
cleavage would be faster than intermolecular cleavage. Thus, this intramolecular cleavage mechanism 
may have been favored in ATs for kinetic reasons. However, no comparison of cleavage rate among 
ATs has been performed yet. Also, whether an intramolecular cleavage catalyzed by the -domain is 
faster than one catalyzed by the passenger domain will depend mainly on the folding state of the 
passenger domain during secretion. Indeed, cleavage in SPATEs occurs immediately after passenger 
translocation is completed and is probably not dependent upon passenger domain folding. In contrast, 
cleavage by the passenger domain requires the passenger domain (or at least domain 1) to be folded in 
the extracellular space. If this domain is not folded during translocation, then cleavage would have to 
“wait” for folding of the proteolytic domain. Considering the slow folding rate of the autotransporter 
in vitro, this might considerably delay cleavage [52]. Thus, the diversity in cleavage mechanisms 
among  ATs  might  lead  to  differences  in  cleavage  rates  or  cleavage  efficiency.  However,  this 
explanation needs to be tested experimentally. Whether such differences would be important for the Toxins 2010, 2                         
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function of these proteins is not known. It is not known either if the cleavage itself is important for the 
virulence function of the SPATEs. It is probable that SPATEs need to be released from the cells (and 
thus cleaved) to reach their host target, but this has not been clearly established. The absence of 
adequate  animal  models  for  most  of  the  SPATE  producing  strains  precludes  the  comparison  of 
pathogenesis between a strain expressing a wild-type SPATE versus one expressing an uncleaved 
SPATE mutant. 
5. Function 
SPATEs were initially identified as proteins secreted by bacterial species that are pathogenic to 
humans or animals (diarrheagenic E. coli and Shigella). Although SPATE genes have now also been 
detected in non-pathogenic strains of E. coli [27], they seem to be more strongly associated with 
pathogenic  strains  [30,67].  As  a  consequence,  numerous  studies  have  been  performed  in  order  to 
identify  their  potential  role  in  pathogenesis.  However,  most  SPATEs  are  produced  by  pathogenic 
species for which relevant animal models of infection are lacking, thus making a clear determination of 
their contribution to disease difficult. Still, the study of these proteins in vitro has provided valuable 
information about their putative role in pathogenesis. 
5.1. Proteolytic Activity 
As previously mentioned, all SPATEs possess a serine protease motif in the first third of their 
passenger domains. The actual proteolytic activity of this domain has been demonstrated for most of 
the family members (exceptions are EaaA, EaaC and Boa, for which protein expression itself has not 
been verified yet). SPATEs are indeed able to cleave various substrate proteins in vitro (Table 2). In 
addition, their membership in the serine protease clan was demonstrated by the use of specific serine 
protease inhibitors and site-directed mutagenesis of the putative catalytic serine present in the motif 
GDSGS.  Both  actions  abolished  proteolytic  activity.  Serine  proteases  rely  on  a  catalytic  triad for 
function. In EspP, the two additional catalytic residues were identified by site-directed mutagenesis as 
Asp156 and His127 [68]. These two amino-acids are, like the serine present in the GDSGS motif, 
conserved  among  SPATEs,  despite  low  sequence  identity  in  the  protease  domain.  Hbp  passenger 
domain structure has been solved (Figure 1, [5]) and shows that the protease domain (also called 
“domain 1”) forms an independent globular domain attached to the -helical “spine” of the passenger 
(Figure 1). Although the proteolytic activity of the isolated domain 1 has not been tested, it seems that 
only this domain is necessary for proteolytic activity. Indeed, mutations abolishing proteolytic activity 
were only identified in this region [68]. This domain adopts a typical chymotrypsin-like fold, with the 
three catalytic residues (Ser207, Asp101 and His73 in Hbp) located in close proximity, thus forming 
the catalytic site on the surface of domain 1 [5]. The structure of Hbp passenger domain is very similar 
to Haemophilus influenzae IgA protease (IgAP) passenger domain [8]. IgAP is an autotransporter 
produced  by  Haemophilus  and  Neisseria,  which  also  displays  a  serine  protease  domain  in  the 
passenger domain. IgAP is involved in the degradation of type 1 immunoglobin A (IgA1), which is 
found in humans and great apes. Specifically, IgAP cleaves after proline residues located in the hinge 
region between the Fc and the Fab domains of IgA1. The structural similarity between Hbp and IgAP 
has led some authors to include IgAP in the SPATE family [8]. However, IgAP, in contrast with Toxins 2010, 2                         
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SPATEs, does not possess a conserved N-terminal extension, is not cleaved between two asparagines, 
nor  does  it  possess  the  FxxEVNNLNK  consensus.  Additionally,  IgAP  is  processed  by  an 
autoproteolytic mechanism that depends on its passenger domain proteolytic activity, rather than upon 
the -domain. Also, IgAP does not possess the conserved -domain sequence found in SPATEs, and is 
not produced by Enterobacteriaceae. Furthermore, whereas IgAP specifically cleaves the hinge region 
of IgA1, none of the SPATEs for which this substrate has been tested do. Thus, despite structural 
homology, these enzymes show a clear difference in substrate specificity. The variation in substrate 
specificity is probably due to the presence of a loop in IgAP, which is absent from SPATEs [5,8,69]. 
This loop was proposed to act as a lid for the IgAP catalytic site that can only be opened upon binding 
to the IgA1 Fc region [8]. Also, the catalytic site of Hbp was found to be much more open than  
IgAP [8,69].  
Table 2. SPATEs substrate specificity. Listed are the substrates for which SPATE activity 
has been tested. 
  Cleaved  Not cleaved 
EatA  AAPM-pNA, AAPL-pNA [25]   
EpeA  pepsin A, gelatin, mucin [16]   
EspC  fodrin [71], hemoglobin [72], pepsin, 
factor V, spectrin (fodrin) [20,40] 
Human IgA1 [71], mucin [40], lysozyme [73] 
EspI  pepsin A, apolipoprotein A1[26]  IgA1, hemoglobin, bovine serum albumin,  
2-macroglobulin, haptoglobin, thrombin, 
collagene type 3, trypsin, high density 
lipoprotein, low density lipoprotein, very low 
density lipoprotein, trypsin, transferrin, 
lactoferrin, pepsinogen, gelatin, casein [26] 
EspP  pepsin A, human coagulation factor 
V [14], casein [15], apolipoprotein 
A1 [26], AAPL-pNA [40] 
human IgA1, bovine serum albumin,  
2-macroglobulin, transferrin, lactoferrin, 
pepsinogen [14], mucin, spectrin (fodrin) [40] 
Hbp  hemoglobin [5]  albumin, human lactoferrin, human 
immunoglobulin A1 [5] 
Pet  casein, gelatin [17], pepsin, human 
coagulation factor V, spectrin [19,40] 
actin [75], mucin [19,40] 
Pic  gelatin,  ovomucin,  bovine  mucin, 
murine  mucin  [18],  human  spectrin 
(fodrin), pepsin A, human coagulation 
factor V [19,40], mucin [19] 
casein, IgA, IgM, IgG, hog gastric mucin [18] 
ovine spectrin [40] 
Sat  casein [22], factor V, spectrin [40]  IgA1 [22], hemoglobin, mucin, pepsin [40] 
SepA  FLF-pNA,  VPF-pNA,  AAPF-pNA, 
AAPM-pNA [70] 
IgA1,  gelatin  [28],  angiotensin-I,  egg 
lysozyme  [70],  fibronectin,  mucin,  pepsin, 
factor V, spectrin (fodrin) [40] 
SigA  casein [29], fodrin [45]   
Tsh  mucin, factor V [40]  human  and  chicken  IgA,  casein,  pepsin  A 
[40,42], spectrin [40] 
Vat    casein [35] Toxins 2010, 2                         
 
 
1192 
Although Hbp is the only SPATE for which a passenger domain structure is available, homology 
modeling of EspP and Pet suggests that these SPATE passenger domains adopt a very similar fold 
compared with Hbp [5,68]. In particular, the domain 1 of EspP was predicted to adopt an elastase-like 
fold, suggesting that in all SPATEs, domain 1 adopts a chymotrypsin-like fold [68]. The variation in 
substrate specificity between SPATEs (Table 2) could then be explained by residue variation in the 
specificity pocket [5]. Although the basis for SPATEs‟ substrate specificity has not been demonstrated, 
a study with SepA and a collection of synthetic oligopeptides suggests that the length of the substrate 
is important for proper cleavage. Also, although SepA interacts with other residues from the cleavage 
site, the residue at position P1 (Phenylalanine in the case of SepA, but Pro for Iga-Pr) is particularly 
important  for  cleavage  [70].  However,  SepA  seems  to  also  interact  with  other  residues  of  the  
cleavage site [70]. In the same study, the optimum conditions for SepA activity were 37 C and near 
neutral pH (7.5) [70].  
The serine protease activity of SPATE passenger domains is not involved in the processing of the 
passenger domain from the -domain and is not related functionally to the proteolytic activity of the  
-domain. In contrast to the -domain proteolytic activity, which is apparently only required for the 
release  of  the  passenger  domain  in  the  extracellular  space,  the  proteolytic  activity  located  in  the 
passenger domain might be important for the virulence of the producing strain. The proteolytic activity 
of SPATE passenger domains has been tested in vitro both on synthetic oligopeptides labeled with 
paranitroanilide (p-AN) or on entire proteins. As can be seen in Table 2, SPATEs are very diverse in 
their substrate specificity.  
Whether the ability of SPATEs to cleave the proteins tested in vitro is relevant to their role in vivo 
is mostly unknown. It has been proposed that the cleavage of mucin might help pathogenic bacteria 
degrade mucus and thus adhere to the mucosa [18]. The cleavage of human coagulation factor V by 
EspP has been suggested to be involved in the hemorrhage observed upon infection by EHEC [14]. 
Finally, fodrin might be the intracellular target of EspC and Pet [40,71]. However, these hypotheses 
have not been tested and for most SPATEs, the actual in vivo target is still unknown.  
5.2. Role in Pathogenesis 
SPATEs have been divided into two sub-groups based upon phylogenic criteria. One group includes 
SPATEs that display cytotoxic activity (Pet, EspC, EspP, SigA) and, which probably have intracellular 
targets. The other group includes SPATEs that do not have demonstrated cytopathic activity on cells, 
but which might be important in pathogenesis because they affect an extracellular target [31]. Here, we 
summarize studies addressing the role of SPATEs in the virulence of their parental strain. 
EaaA/EaaC: eaaA and eaaC are two genes that have been identified in the non-pathogenic E. coli 
strain ECOR-9 (this strain was isolated from the feces of a healthy Swedish child). The two genes are 
located on prophages and are linked to genes encoding non-SPATE, trimeric autotransporters involved 
in non-immune IgG and IgA binding (eib “E. coli Ig binding” genes). eaaA and eaaC are 99.4% 
identical at the nucleotide level and encode proteins homologous to the SPATE proteins. The actual 
expression of eaaA and eaaC in ECOR-9 or the role of these genes has not been tested [27]. Although 
autotransporters  are  often  referred  to  as  virulence  factors,  the  presence  of  these  genes  in  a  non-
pathogenic strain of E. coli suggests that SPATE proteins might not all be virulence factors per se. Toxins 2010, 2                         
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Certain SPATEs might be important for colonization of the gastrointestinal tract by commensal strains, 
but this needs to be tested. 
EatA: EatA is produced by enterotoxigenic strains of E.coli (ETEC), which are a major cause of 
diarrhea  in  developing  countries.  EatA  is  73%  identical to  SepA and  displays  similar enterotoxic 
effects in the rabbit ileal loop model of infection. In a manner that is similar to a Shigella sepA mutant 
[28], at 7 h following infection, a ETECeatA mutant caused less fluid accumulation and mucosal 
destruction  in  this  model  than  the  wild-type  strain  would.  However,  after  16  h  of  infection,  no 
difference was observed between the mutant and the parental strain (sepA effects 16 h after infection 
were not reported [28]). These results suggest that EatA is not necessary for ETEC virulence, but 
might accelerate the development of the disease. Whether EatA proteolytic activity is necessary for 
this effect has not been tested. Indeed, EatA, like other SPATEs, is a serine protease. EatA cleaves the 
oligopeptide  methoxysuccinyl  (MeOSuc)-Ala-Ala-pro-Met-p-nitroanilide  (AAPM-pNA:  100% 
activity) in vitro, as well as AAPL-pNA (80%), AAPF-pNA (10%), VPF-pNA (30%) and FLF-pNA 
(10%)  [25].  The  substrates  cleaved  by  EatA  in  vitro  are  also  substrates  for  cathepsin  G  (an 
antibacterial serine protease secreted by polymorphonuclear leukocytes) and SepA. However, despite a 
strong  homology  with  EatA,  SepA  levels  of  activity  on  these  substrates  are  different:  50%  for  
AAPM-pNA and AAPF-pNA: 50%, 100% for VPF-pNA, and 80% for FLF-pNA [70].  
EpeA: epeA was identified by sequencing the plasmid pO113 transfer region from non-LEE EHEC 
[16]. EpeA expression was verified and its toxic effect on HeLa cells was tested. In contrast with 
EspP, Pet, SigA or Sat, no toxicity was observed when purified EpeA was applied on HeLa cells [16]. 
This is consistent with the split decomposition analysis from Yen et al. that shows that EpeA belong to 
the non-cytotoxic group of SPATEs [31]. 
EspC: Upon infection,  EPEC form characteristic “attaching and  effacing” (A/E) lesions on the 
intestine mucosa. These lesions are characterized by the effacement of microvilli and the formation of 
an actin pedestal underneath the adherent bacterium. Although the role of these lesions in pathogenesis 
is not clear, factors involved in their formation are important for virulence. EspC is secreted by EPEC 
and was initially shown to associate with HeLa cells in vitro, suggesting that it might have a role in 
virulence. However, an espC deletion mutant was not different from its isogenic EPEC parent in terms 
of adherence or invasion of HeLa, HEp-2, or polarized Caco-2 cells. In addition, EspC was shown not 
to  be  involved  in  the  formation  of  A/E  lesions:  first,  the  espC  mutant  was  not  affected  in  
EPEC-mediated epithelial cell signaling, cytoskeletal rearrangements, or Tir-phosphorylation, all of 
which are necessary for A/E lesion formation [41]. Second, EspC was not detected in several other 
pathogens, such as Hafnia alvei or Citrobacter freundii, which also form A/E lesions, indicating that 
EspC is not required for this phenomenon to occur [20]. EspC also does not appear to be involved in 
inhibition of complement killing or hemagglutination [20]. However, EspC mediates EPEC lysozyme 
resistance, by an unknown mechanism independent of its proteolytic activity. This could be important 
for initial steps of the disease and resistance of the bacterium to non-specific host defense [73]. Also, 
purified EspC displays enterotoxic activity on rat jejunal tissue mounted in Ussing chambers [33] as 
well as cytotoxicity on epithelial cells in vitro [71]. The effects of purified EspC on epitelial cells 
(formation  of  vacuoles,  cell  contraction,  cells  detachment  and  rounding,  membrane  blebs  and 
cytoskeletal damage) were similar to those observed with another SPATE: Pet. However, compared 
with Pet, EspC required a longer incubation time with cells and a higher concentration to produce the Toxins 2010, 2                         
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same effects [71]. Whether the enterotoxic effect of EspC was dependent upon its proteolytic activity 
was not tested [33]. In contrast, the cytotoxic effect of purified EspC on epithelial cells was dependent 
on  the  protease  activity  of  the  passenger  domain:  addition  of  the  protease  inhibitor  PMSF 
(phenylmethylsulfonyl fluoride) eliminated all cytotoxic effects, and no cytotoxicity was observed in 
cells incubated with a EspC mutant defective in protease activity (S256I) [71]. A potential intracellular 
substrate for EspC is fodrin, a ubiquitous protein involved in actin crosslinking, which is also cleaved 
by the SPATE Pet. EspC binds and cleaves fodrin in vitro and the cleavage sites recognized by EspC 
in fodrin are different from those recognized by Pet. Also, whereas fodrin cleavage by Pet triggers 
foldrin redistribution in HeLa cells, such effects were not observed upon incubation of cells with 
EspC [74]. However, whether EspC actually cleaves fodrin in vivo or whether the cytotoxic effects 
induced by EspC are due to fodrin cleavage has not been determined. It is currently not known if the 
cleavage  of  other  EspC  substrates  identified  in  vitro  (hemoglobin,  mucin  etc.)  is  physiologically 
relevant and has any role in pathogenesis. Finally, EspC cytotoxic effects are strictly dependent upon 
the protein internalization in the cytoplasm of epithelial cells. Purified EspC can be internalized by 
pinocytosis in a receptor-independent fashion when added to epithelial cells at high concentration for a 
long (8 h) incubation time [75]. However, this process is not efficient, nor physiologically relevant, 
since it does not involve any receptor or intracellular trafficking. In contrast, when EPEC infects cells, 
EspC is efficiently internalized by a mechanism that depends upon the presence of a functional type III 
secretion system. Although EspC is secreted by the type V secretion system, it then interacts with 
components of the EPEC Type III secretion system (EspA, the tip protein) and is internalized by a 
process dependant upon this system. Interestingly, this internalization can also be triggered by T3SS 
from other strains, such as EHEC or REPEC. This process is highly specific for EspC since another 
SPATE (Pic) was not internalized in the same conditions [76]. It is generally assumed that type III 
secretion systems translocate proteins directly from the cytoplasm of the bacterium to the cytoplasm of 
eukaryotic  cells  in  one  step  through  a  closed  conduit.  How  exactly  EspC  “hijacks”  the  type  III 
secretion system from the extracellular medium, where it is secreted, to gain access to the eukaryotic 
cell cytoplasm is not known. EspC interacts with EspA, the EPEC T3SS tip protein, which is exported 
by the T3SS and assembled at the tip of the needle following completion of the needle structure. Then, 
the T3SS interacts with host cells and forms a pore in the host cell membrane through which T3SS 
effectors can be translocated [77]. Since EspC is the first protein secreted by EPEC upon infection 
[41],  the  interaction  between  EspA  and  EspC  could  be  taking  place  while  the  needle  is  being 
assembled, before the needle actually interacts with the cell. If this is the case, EspC would be already 
localized at the tip of the needle when the EspD/B pore is formed in the host cell membrane. Thus, 
EspC might use this pore to gain access to the host cell cytoplasm. However, if this is true, EspC might 
not be able to gain access to the pore once the T3SS apparatus is finalized and a closed channel is 
formed between the bacterial cytoplasm and the host cell cytoplasm. As a consequence, EspC could 
only  be  internalized  if  synthesized  before  or  during  the  T3SS  needle  assembly.  Thus,  delaying 
expression of EspC would probably reduce its internalization. In addition, it has been estimated that 
the pore formed by T3SS in the host membrane is ~25Å wide [78], which is too small to accommodate 
a folded protein the size of EspC. Thus, EspC would have to be unfolded if it were to use this pore for 
internalization.  Another  possibility  would  be  that  EspC  interaction  with  EspA  is  a  way  for  the 
bacterium to avoid diffusion of EspC in the medium after secretion or to target EspC to the host cell, Toxins 2010, 2                         
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or both. After reaching the cell membrane via the T3SS, EspC could then be translocated through the 
host  membrane  by  a  T3SS-independent  mechanism.  For  example,  EspC  could  use  a  “membrane 
puncturing” mechanism similar to the one used by the T4 phage gp5 needle protein or the Vibrio 
cholerae T6SS VgrG protein: both of these proteins form long -helices that are able to perforate 
membranes  without  the  need  of  a  pore  or  a  dedicated  translocase  [80].  Also,  VacA,  a  
non-SPATE autotransporter that folds as a -helix [7], is able to insert in cell membrane, where it 
forms pore [81]. Thus, -helical proteins seem to have a certain ability to insert into membrane, and 
since EspC, like most autotransporter passenger domains, is predicted to fold as a long -helix, it 
might also be able to insert in the membrane independently of the T3SS. However, although EspC 
might cross the host membrane by itself, the interaction with the T3SS needle might be important for 
proper  orientation  of  EspC  toward  the  membrane  (most  likely  perpendicular  to  the  plane  of  the 
membrane) or to provide the energy required for translocation through the host membrane, or both. 
EspI: espI was identified as one of the ORFs present in a novel pathogenicity island found in the 
STEC subgroup that lacks the locus of enterocytes effacement (LEE). Like EspP, EpeA, EspC, Pet, 
and Pic, purified EspI is able to digest pepsin A1. However, like EpeA, it is unable to elicit toxic 
activity when applied to Vero cells [26], suggesting that, like EpeA, EspI belongs to the subtype of 
SPATE that possesses an extracellular target, rather than an intracellular one. This classification of 
EspI is supported by the phylogenetic studies of Yen et al. [31]. Interestingly, EspI was also found to 
cleave apolipoprotein A-I, a protein present in human serum, but whether this is the actual target of 
EspI in vivo is not known [26]. 
EspP/PssA: EspP/PssA is produced by EHEC [14,15]. EspP/PssA was shown to induce cytotoxic 
effects on Vero cells. In a manner similar to EspC and Pet, purified EspP/PssA induced cytoskeletal 
damage, with loss of stress fiber, disruption of actin cytoskeleton, cell detachment and rounding, and 
opening of the cell-cell junction [15] Whether EspP/PssA is, like Pet and EspC, internalized by host 
cells is not known. Also, the role of EspP/PssA proteolytic activity in its cytotoxicity has not been 
reported, but it is possible that EspP also cleaves fodrin in vivo, since the cytopathic effects observed 
with EspP/PssA are similar to the ones observed with EspC and Pet, both of which target fodrin. In 
addition, a role for EspP/PssA in intestinal colonization of cattle was suggested by isolation of the 
pssA mutant in a signature-tagged mutagenesis screen [81]. EspP/PssA was also proposed to have a 
role in E. coli O157:H7 colonization of intestinal mucosa and adherence based upon experiments done 
with an E. coli O157:H7 espP::kan
R mutant, which was shown to be slightly affected in adherence to 
cultured cattle rectal cells in vitro [82]. In a more recent study, a espP derivative of the E. coli 
O157:H7 strain EDL933, when compared with the parental strain, was also deficient in adherence to 
T84  colonic  adenocarcinoma  cells  in  vitro  [83].  However,  when  EHEC  O157:H7  is  cured  of  the 
plasmid pO157 (which encodes EspP), the pathogenesis in gnotobiotic piglets is not affected [84]. 
Interestingly,  espP  was  also  one  of  the  genes  isolated  in  a  screen  for  genes  involved  in  biofilm 
formation [83]. The role of EspP proteolytic activity in adherence or biofilm formation has not been 
investigated. Finally, cleavage of coagulation factor V by EspP has been proposed to be involved in 
the hemorrage observed during EHEC infection; however this has not been proven yet.  
Hbp: Hbp “hemoglobin protease” or “hemoglobin binding protein” was initially identified in an  
E. coli strain (EB1) isolated from a patient presenting a wound infection [21]. Hbp can interact with 
heme and hemoglobin in vitro, but has better affinity for hemoglobin than heme. Hbp can also degrade Toxins 2010, 2                         
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hemoglobin,  by  a  mechanism  dependent  upon  its  serine  protease  activity.  Although  it  has  been 
proposed that the Hbp heme-binding domain could be located between residues 608 and 644, this has 
not been tested experimentally [85]. The hemoglobin-binding domain is not known either. The Hbp 
passenger domain crystal structure has been resolved, but only in the apo form [5]. Thus, no information 
is  currently  available  on  the  heme  binding-site  location  or  on  potential  conformational  change(s) 
occurring  in  the  protein  after  heme  or  hemoglobin  binding  [5].  Because  Hbp  is  secreted  in  the 
extracellular milieu and binds heme, it was proposed to be part of an iron acquisition system. In gram-
negative bacteria, heme-acquisition occurs by two distinct mechanisms. In one mechanism, bacteria 
directly bind heme or the heme source through a membrane receptor and then transfer the heme into 
the  bacterial  cytoplasm.  In  the  second  mechanism,  the  bacterium secretes  a  heme-binding protein 
(hemophore) into the milieu. This hemophore scavenges heme from hemoproteins and then shuttles 
heme back to the bacteria, where it interacts with a specific receptor. Although Hbp is similar to 
hemophores because it is secreted and binds heme, it is also a protease, which degrades hemoglobin. 
Thus,  Hbp  could  participate  in  heme-acquisition  by  either  of  the  two  mechanisms.  In  one  case,  
Hbp-mediated hemoglobin degradation could release free heme molecules into the medium. These 
molecules  would  subsequently  be  taken  up  by  a  bacterial  heme-receptor  such,  as  E.  coli  ChuA. 
However, because Hbp binds heme with high affinity, the release of free heme in the media would 
probably need to occur after all Hbp molecules have been converted to holo-Hbp. Assuming that 
heme-binding does not affect Hbp proteolytic activity (which to our knowledge has not been tested), 
cleavage of hemoglobin by holo-Hbp would release free heme in the environment (because no empty 
heme binding pocket is available on Hbp). Because hemoglobin triggers release of Hbp from hemin-
agarose [5], it is also possible that holo-Hbp releases the bound heme molecule when interacting with a 
new molecule of hemoglobin. Alternatively, Hbp could act as a hemophore: in which case it can bind 
hemoglobin, degrade it, and bind the released heme. Then, holo-Hbp would need to deliver the bound 
heme  to the bacterium. However, no receptor for Hbp on the bacterial outer membrane has been 
identified so far. The Hbp beta-barrel, which would be left in the bacterial membrane after cleavage 
and release of the passenger, is probably not this receptor since Hbp has been shown to deliver heme to 
Bacteroides fragilis, which does not express Hbp [85]. The ability of B. fragilis to capture heme from 
E.coli Hbp is probably one of the reasons for the synergy of abscess formation in intra-abdominal 
infections caused by E. coli and B. fragilis. Indeed, Hbp is essential for abscess formation in the 
context of coinfection by E. coli and B. fragilis. Immunization of mice with Hbp prevented such 
abscess formation [85].  
Whether  Hbp  acts  as  a  hemophore  or  only  as  a  hemoglobin-protease  has  not  been  clearly 
established  yet.  However  experiments  performed  with  B.  fragilis  suggest  a  role  for  Hbp  as  a 
hemophore. Growth of  B. fragilis  can  be  made  heme-dependent in  certain medium [85]. In these 
conditions, growth is stimulated upon addition of heme or purified holo-Hbp to the medium. Apo-Hbp, 
in contrast, does not promote growth. The effect observed with holo-Hbp was not due to the release of 
free heme from Holo-Hbp, because (1) twice as much free heme was required to give the same effect 
as holo-Hbp (heme and Hbp bind in a 1:1 ratio) and (2) antibodies directed against Hbp abolished 
holo-Hbp  growth  induction  [85].  These  results  suggest  that  B.  fragilis  has  a  specific  receptor  for  
holo-Hbp and can transfer heme from holo-Hbp. Whether E. coli EB1 (the strain in which Hbp was 
initially identified) also has such a receptor remains to be determined. Toxins 2010, 2                         
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Finally,  the last  possibility would be that holo-Hbp transfers heme to another hemophore with 
higher affinity for heme and that this second hemophore then shuttles the heme back to the bacteria. 
However, such a mechanism has never been described and we are not aware of any other heme-
binding protein secreted by E.coli EB1.  
The ability to cleave hemoglobin has been tested only for a few of the other SPATEs; whereas Sat 
and EspI do not process hemoglobin [26,40], EspC and Pic do [67], but in these cases the binding to 
heme has not been tested. Thus, whether EspC and Pic could also be part of iron acquisition systems is 
not known.  
Finally, Hbp and Tsh only differ by two residues (Q209K and A842T). Tsh, like Hbp was able to 
induce abscess formation in a mouse model of coinfection with B. fragilis, suggesting that it also has 
the  ability  to  cleave  hemoglobin  and/or  bind  heme.  However  no  report  of  such  activity  is  
available  [81].  However,  Hbp,  in  contrast  with  Tsh,  does  not  show  any  mannose-resistant 
hemagglutination activity, at least not in the conditions tested [21], suggesting that the two divergent 
residues are important for this particular activity, but not for abscess formation. 
Pet:  Pet  was  the  first  autotransporter  for  which  an  enterotoxic  activity  was  reported  [17]. 
Specifically, Pet shows enterotoxic activity on rat jejunal tissue mounted in Ussing chambers [17,86]. 
Pet  also  causes  cytotoxic  effects  on  these  same  cells:  tissue  damage,  inflammation,  and  mucus 
secretion were observed [86]. Furthermore, Pet was found to induce cytopathic effects on HEp-2 and 
HT29 C1 cells. Both enterotoxic and cytotoxic activity are dependent upon the proteolytic activity of 
the Pet passenger domain, since a mutant in the catalytic serine is not toxic and the use of serine 
protease inhibitors abolishes these toxic effects [82]. In a manner similar to EspC, Pet toxic effects 
require  internalization  of  the  protein  into  host  cells.  However,  in  contrast  with  EspC,  the 
internalization  of  Pet  occurs  by  Clathrin-dependent  endocytosis  [87].  After  endocytosis,  Pet  is 
trafficked to the endoplasmic reticulum and back to the cytosol [88]. Once in the cytoplasm, Pet 
cleaves the same substrate as EspC: fodrin (-spectrin). This cleavage induces a redistribution of 
fodrin and the cytopathic effects observed. 
Pic: Pic is produced by Shigella flexneri, EAEC, and UPEC [18,19]. Pic was shown to mediate 
serum  resistance  by  a  mechanism  dependent  upon  its  proteolytic  activity.  Although  the  exact 
mechanism  of  this  serum  resistance  is  not  known,  it  is  probable  that  Pic  degrades  one  of  the 
components of the complement classical pathway of activation [18]. Pic also mediates species-specific 
hemagglutination (weak hemagglutination was observed for rat, pig, rabbit, horse, and sheep red blood 
cells,  but  none  was  observed  with  human  or  chicken  red  blood  cells)[18].  No  effect  of  Pic  as  a 
cytotoxin was detected [86]. However, it was shown that Pic can cleave fodrin, the intracellular target 
of EspC and Pet cytotoxins [19]. In UPEC, the wild-type strain does not have an advantage over a pic 
mutant in colonization of the urethra, bladder, or kidney [89]. In contrast, in streptomycin-treated 
mice, EAEC strain 042 was more efficient at colonizing the gastrointestinal tract than either a pic 
mutant  or  a  strain  expressing  Pic  with  no  proteolytic  activity  (042PicS258A)  [90].  However,  the 
difference in  colonization  did  not  correlate with  a  variation in adherence or growth  ex vivo, thus 
suggesting another role for Pic. Interestingly, it was shown that 042PicS258A is affected in its ability 
to grow in the presence of mucin in vitro. It was therefore proposed that Pic might have a nutritional 
role in colonization. Specifically, Pic may allow bacteria to use mucus or mucin as a nutrients source 
when other sources are not available [90]. Toxins 2010, 2                         
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Sat: Sat is produced by UPEC, a leading cause of urinary tract infection. Sat is cytotoxic on VERO 
kidney cells, HK-2 human bladder, and HEp-2 cell lines. Like Pet or EspC, Sat contact with culture 
cells leads to cell elongation and detachment from their support [22]. Sat also causes vacuolation of 
bladder and kidney cells [91]. This activity is dependant upon the protease activity of Sat and upon its 
internalization in host cells [92]. The ability of Sat to cleave fodrin in vitro suggests that, like EspC 
and  Pet,  Sat  might  target  fodrin  in  vivo.  No  difference  between  wild-type  and  sat  mutant  were 
observed  in  a  short-term assessment of colonization  in  a  mouse model of ascending urinary tract 
infection [22]. However, less cellular damages were observed in the kidneys of mice infected with a 
sat mutant than in those infected with the wild-type strain, thus suggesting that Sat acts mainly as a  
toxin [92]. In contrast with Tsh, Sat did not exhibit any hemagglutinin activity [22]. The sat gene is 
also found in Shigella and DAEC. In DAEC, Sat was shown to promote lesions in tight junctions 
between intestinal epithelial cells. This activity was dependent upon the proteolytic activity of Sat, but 
the exact target in unknown [93]. 
SepA: SepA is one of the SPATEs produced by Shigella flexneri, the agent of Shigellosis, a disease 
in which bacteria invade the colonic mucosa and trigger a strong inflammatory response. SepA is 72% 
identical to EatA, an enterotoxin produced by ETEC (see above). SepA is not involved in bacterial 
entry in HeLa cells, plaque formation on Caco-2 cells, or dissemination between cells [28]. However, a 
sepA mutant is attenuated in the rabbit model of ligated ileal loop. Infection with this mutant indeed 
causes  reduced  fluid  accumulation,  reduced  mucosal  atrophy  and  decreased  tissue  inflammation 
compared with the wild-type strain 8h after inoculation [28]. However, the effect of SepA in the rabbit 
ileal loop model was not tested at later time points, and in the case of EatA, although similar, toxic 
effects were seen 7 h after infection, after 16 h, no difference between the mutant and the wild-type 
subsisted [25]. Thus, it is possible that SepA, like EatA, is not essential for the establishment of the 
disease but increases the disease‟s rate of progression. The role of SepA proteolytic activity in its 
enterotoxic activity was not tested [28]. SepA substrate specificity, however, was tested in vitro on 
synthetic peptides, and showed similarity to cathepsin G. However, in contrast with cathepsin G, SepA 
was not able to activate platelets, cleave thrombin receptors, fibronectin, collagen or angiotensin I. 
This  indicates  that  despite  in  vitro  similarity,  the  SepA  in  vivo  target  is  probably  not  one  of  the 
cathepsin G substrates [70]. As discussed earlier, SepA substrate specificity is also similar to EatA, but 
the level of activity on the substrates differs between the two SPATEs, suggesting that they probably 
do not share the same in vivo target either [25,70]. 
SigA: SigA is produced by Shigella flexneri. A culture supernatant containing SigA caused damage 
to HEp-2 cell culture (cell rounding and detachment). However, the effects were less pronounced than 
the similar effects seen for Pet. Addition of a protease inhibitor abolishes toxicity, indicating that the 
damage is caused by the ability of SigA to cleave a host target [29]. Indeed, SigA, like Pet and EspC, 
was shown to degrade fodrin in vitro and in situ [45]. The cleavage of fodrin in situ by SigA causes its 
redistribution within the cell [45]. In contrast with Pet and EspC, the mechanism of entry of SigA in 
target cells and the trafficking route following entry has not been determined. 
Tsh:  The  Tsh-encoding  gene  was  initially  identified  as  a  gene  from  avian  pathogenic  E.  coli 
(APEC) strain 7122. The gene confers hemagglutination properties to E. coli K12 [23]. APECs are 
pathogenic strains of E. coli that cause extraintestinal infection in poultry. APEC infections affect the 
respiratory  tract,  but  can  also  become  generalized  and  cause  fatal  septicemia  in  animals.  Tsh Toxins 2010, 2                         
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hemagglutination activity was not abolished in a strain expressing a mutant where the Tsh catalytic 
serine was changed to threonine or alanine, suggesting that the hemagglutinin activity is independent 
from  the  proteolytic  activity  [42]  Interestingly,  Tsh-producing  strain  7122  was,  like  the  
Hbp-producing strain, able to induce a synergistic interaction with B. fragilis in a mouse model of 
intra-abdominal abscess formation [85]. This suggests that Tsh, like Hbp, can degrade hemoglobin and 
transfer heme obtained from hemoglobin degradation to B.fragilis. Indeed, Tsh was shown to bind 
hemoglobin [94]. Tsh also binds collagen IV and fibronectin, suggesting that it might act as an adhesin 
[94].  Tsh,  in  contrast  with  Pic,  does  not  mediate  serum  resistance  [32],  but  was  proposed  to  be 
important for the colonization of the chicken air sac. Indeed, a tsh knockout mutant of E.coli 7122 
causes fewer and less pronounced lesions in these organs in comparison with the parental strain [32]. 
Tsh  is  also  expressed  by  UPEC,  but  the  role  of  Tsh  in  urinary  tract  infections  has  not  been  
investigated [89]. 
Vat: APEC causes extraintestinal infection in poultry, such as respiratory diseases, cellulites, or 
septicemia. Vat, like Sat and EspC, has vacuolating activity: it induces the formation of intracellular 
vacuoles in cell culture. No vacuolating activity was reported for Tsh despite being 75% identical to 
Vat. A vat mutant was attenuated in a cellulite model of infection in chicken [35], suggesting a role for 
this protein in infection. Whether this activity is, like for Sat, linked to its protease activity is not 
known. So far no substrates have been identified for Vat. Interestingly, Vat is the only SPATE for 
which the serine protease consensus is not perfectly conserved (ATSGSP instead of GDSGSP). Thus, 
the  proteolytic  activity  and  substrate  specificity  of  this  particular  SPATE  would  be  particularly 
interesting to look at.  
6. Conclusions 
Autotransporters are an expanding family of secreted proteins from gram-negative bacteria. Over 
the past two decades, numerous studies have focused on elucidating the secretion mechanism of these 
proteins. However, so far, the mechanism by which these proteins cross the outer membrane remains 
controversial.  The  discrepancy  of  data  obtained  between  different  studies  actually  suggests  that 
different autotransporters might use different secretion mechanisms. It is already known that these 
proteins  show  variations  in  their  biogenesis  (cleavage  mechanism,  chaperone  requirement)  and 
function (protease, adhesins). Thus, differences in secretion would not be that surprising. The AT 
variety is particularly striking in the SPATE family of autotransporters. Although SPATEs are much 
more  conserved  than  other  autotransporters,  discrepancies  are  also  observed  between  studies 
addressing their secretion mechanism. Whether this is due to variation in experimental conditions or 
not will need to be addressed in the future. In addition, SPATEs show huge diversity in function. All 
these proteins are serine proteases, and probably adopt a similar fold, but still, they do not share the 
same targets. In addition, their effect on cells varies: some SPATEs are cytotoxins, while others are 
not. The mechanism SPATE cytotoxins use to enter host cells also varies. Their trafficking routes 
inside these cells also vary. Still, all these proteins have effects in vitro that suggest they are somehow 
involved  in  the  pathogenesis  of  their  parental  strain.  Currently,  the  determination  of  the  role  of 
SPATEs in pathogenesis is limited by the lack of small-animal models of infection. Hopefully, the 
development of new animal models will permit precise understandings of the roles these proteins play Toxins 2010, 2                         
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in establishment of disease. Meanwhile, a lot of questions regarding the evolution and biogenesis of 
SPATEs remain to be answer, including: what is the common ancestor of SPATEs? What exactly is 
the role of the N-terminal extension, and why is it so conserved in SPATEs? What is the role of the 
autocleavage?  Why  do  SPATEs  not  use  their  serine  protease  activity  to  cleave  their  passenger 
domains,  like  other  serine  protease  autotransporters?  What  is  the  molecular  basis  for  substrate 
recognition and specificity? How is SPATE expression regulated? What differentiates SPATEs that 
are internalized in host cells from SPATEs that are not? 
Considering that most SPATEs are proven or putative virulence factors, understanding the details of 
their biogenesis and function would be particularly useful in designing new antimicrobial therapies. 
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